Madrigal Pharmaceuticals stock

MDGL · NASDAQ · USD

Compare Madrigal Pharmaceuticals
$421.99Change from previous close: −0.46%Absolute change: −$1.97

Close · November 17, 2026

Price history

−23.30% over the period

1 year: from $553.42 (November 17, 2025) to $424.48 (November 17, 2026), −23.30%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 17, 2026$424.48
October 30, 2026$430.36
September 30, 2026$503.96
August 31, 2026$540.03
July 31, 2026$467.32
June 30, 2026$536.95
May 29, 2026$497.27
April 30, 2026$517.39
March 31, 2026$523.47
February 27, 2026$432.00
January 30, 2026$489.31
December 31, 2025$582.34
November 28, 2025$596.98
November 17, 2025$553.42

At a glance

  • The company

    Biopharmaceutical company developing novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH)

  • Latest results

    Quarter to June 30, 2026 · EPS -$1.99 (estimate -$2.75)

TickerLandia's take on Madrigal Pharmaceuticals

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$353.54
52-wk high$615.00

−31.38% from the 52-week high

Analysts · 19 analysts

Average target$688.78+63.22% vs. price

Buy 18 · Hold 1 · Sell 0 · Strong buy

TickerLandia Fingerprint: Madrigal Pharmaceuticals

Compared with similar companies: very weak momentum.

Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.

1 dimension without enough data. Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 17, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Madrigal Pharmaceuticals is pricier than similar companies

Madrigal Pharmaceuticals's Forward P/E: 38.1, +136% against the median of a group of 7 similar companies (16.1).

Compared with 7 similar companies

Madrigal Pharmaceuticals's metrics compared with similar companies
MetricMadrigal PharmaceuticalsPosition in the groupBand
Forward P/E38.1High
Operating margin-10.7%Middle
ROE-24.8%Low
Debt/equity0.56Middle
Price/book15.8Middle

Grey band: the middle half of the group; tick: the median; dot: Madrigal Pharmaceuticals. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$364.25M

Latest quarter · Q2 2026

Net income

-$57.94M

Latest quarter · Q2 2026

Quarterly net margin

-15.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$9.93B
EPS
-$5.85
Volume
441.25K
Daily trading
€223.02M
Dividend yield
0.00%

How Madrigal Pharmaceuticals is changing

All results
  • Shares outstanding up 45.2% in 5 years

  • Profitable in 0 of 5 fiscal years

Returns

Madrigal Pharmaceuticals returns

$1,000 invested in Madrigal Pharmaceuticals 5 years ago, on November 17, 2021, would be worth $4,881 today: +388.13% in total, +37.32% per year. This is the price return only: dividends are excluded.

PeriodMadrigal PharmaceuticalsS&P 500$1,000 becomes
1 month−5.06%−3.17%$949
6 months−19.42%+0.11%$806
Year to date−27.11%+8.34%$729
1 year−23.30%+11.15%$767
3 years+140.28%+64.30%$2,403
5 years+388.13%+58.18%$4,881
10 years+2,449.43%+239.10%$25,494

Over the last 6 months it has done better than 9% of the stocks in the Healthcare sector.

Price only, without dividends. Calculate your investment

The chart in detail

Madrigal Pharmaceuticals: technical analysis

Madrigal Pharmaceuticals is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 30.0% below its all-time closing high ($602.83, December 22, 2025).

Trend
Downward
RSI (14 sessions)
40
Between 30 and 70
vs 200-session average
−14.81%

Support and resistance

Price areas where Madrigal Pharmaceuticals has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$487.41+15.50%4 touches, last on November 3, 2026
  2. Resistance$461.62+9.39%3 touches, last on June 11, 2026
  3. Resistance$446.11+5.71%2 touches, last on July 30, 2026
  4. Last price$421.99
  5. No support below: the price is near the lows of the year

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.44
Volatility (60 sessions, annualised)
34.9%
Largest fall in the last year
−34.26%

Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Madrigal Pharmaceuticals: seasonality

Average monthly price change over 20 years

+1.4%Jan−0.7%Feb−0.9%Mar+7.5%Apr+4.6%May−4.7%Jun+0.4%Jul+2.9%Aug+6.5%Sep−1.6%Oct+6.4%Nov+23.1%Dec

Over the last 20 years, the strongest month for Madrigal Pharmaceuticals has been December: +23.10% on average, positive in 10 years out of 19. The weakest has been June: −4.74% on average, positive in 9 years out of 20. November, the current month, has been positive in 12 years out of 19 (+6.41% on average).

Show chart data
MonthAverageMedianPositive years
January+1.42%−0.69%9 of 19
February−0.68%+2.05%12 of 19
March−0.92%−4.03%7 of 20
April+7.53%+0.90%11 of 20
May+4.59%−5.02%7 of 20
June−4.74%−1.32%9 of 20
July+0.41%−4.80%6 of 20
August+2.92%−1.98%10 of 20
September+6.46%−5.13%9 of 20
October−1.60%−2.11%9 of 20
November+6.41%+6.38%12 of 19
December+23.10%+2.45%10 of 19

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Madrigal Pharmaceuticals and its competitors

Madrigal Pharmaceuticals, Inc. recorded revenue of $958.4 million in the fiscal year ended December 2025, and its work is concentrated on metabolic dysfunction-associated steatohepatitis, or MASH, a form of liver disease. The biopharmaceutical company develops novel therapeutics for this condition, with a focus on the United States market. Its main product is Rezdiffra, a liver-directed thyroid hormone receptor beta agonist used for treating MASH, which is the basis of its commercial activity.

Headquarters
West Conshohocken, United States
Employees
915
Founded
2011
Chief executive
William Sibold
Madrigal Pharmaceuticals and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
Madrigal PharmaceuticalsMDGL$9.93B-10.7%—−19.42%
Corcept TherapeuticsCORT$9.36B0.8%190.2+24.30%
BioMarin PharmaceuticalBMRN$11.09B16.3%146.8+12.93%
Summit TherapeuticsSMMT$11.32B0.0%—−36.75%
Bio-TechneTECH$11.43B21.7%66.8+67.74%
Twist BioscienceTWST$7.4B-28.8%—+127.78%

Same industry or related industries, similar size. Compare Madrigal Pharmaceuticals with its competitors · Full profile